Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading X4 Pharmaceuticals Inc chart...

About the Company

x4 pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and reverse immune suppression, which is fundamental to treating cancer and certain rare, genetic primary immunodeficiency diseases. our oral, small molecule drug candidates inhibit the binding of chemokine cxcl12 to c-x-c receptor type 4 (cxcr4), a receptor-ligand pair that plays an essential role in normal immune surveillance. we are committed to advancing the fields of cancer immunotherapy and genetic immune disorders through innovation and investment in our proprietary clinical and preclinical pipeline. x4’s most advanced product candidate, x4p-001-rd, is in a phase 2/3 study in patients with whim syndrome, a rare genetic, primary immunodeficiency disease. x4p-001-io is currently under investigation in multiple phase 1/2 studies in refractory clear cell renal cell carcinoma (ccrcc) and melanoma. our third program, x4p-002, is in preclinical development and designed specifically for the t

CEO

Paula Ragan

Exchange

NASDAQ

Website

http://www.x4pharma.com/

$12M

Total Revenue

83

Employees

$153M

Market Capitalization

-1.41

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $XFOR News

X4 Pharmaceuticals Inc XFOR

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17d ago, source: Nasdaq

the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used ...

X4 Pharmaceuticals, Inc. (XFOR)

3d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17d ago, source: Stockhouse

the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement ...

X4 Pharmaceuticals, Inc.

28d ago, source: CNN

X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment ...

X4 Pharmaceuticals Inc XFOR

5d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

X4 Pharmaceuticals Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

XFOR X4 Pharmaceuticals, Inc.

1mon ago, source: Seeking Alpha

**NM signifies a non meaningful value. A dash signifies the data is not available.

X4 Pharmaceuticals, Inc. (XFOR)

22d ago, source: Yahoo Finance

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2023 Earnings Call Transcript November 9, 2023 X4 Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.15.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...